Anti‐factor IXa/X bispecific antibody ( ACE 910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation-Reference-Cited by-同舟云学术

Anti‐factor IXa/X bispecific antibody ( ACE 910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

Published:2014-02 Issue:2 Volume:12 Page:206-213
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Muto A.¹,Yoshihashi K.¹,Takeda M.¹,Kitazawa T.¹,Soeda T.¹,Igawa T.¹,Sakamoto Y.¹,Haraya K.¹,Kawabe Y.¹,Shima M.²,Yoshioka A.³,Hattori K.¹

Affiliation:

1. Research Division Chugai Pharmaceutical Co., Ltd Gotemba Shizuoka Japan

2. Department of Pediatrics Nara Medical UniversityKashihara Nara Japan

3. Nara Medical University Kashihara Nara Japan

Funder

Chugai Pharmaceutical Co., Ltd.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12474

Reference19 articles.

1. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia

2. Modern haemophilia care

3. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

4. The principal results of the International Immune Tolerance Study: a randomized dose comparison

5. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy;Thrombosis and Haemostasis;2024-08-12

2. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents;Seminars in Thrombosis and Hemostasis;2024-06-12

3. Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia;Thrombosis Research;2024-05

4. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A;Haemophilia;2024-04-29

5. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice;Thrombosis and Haemostasis;2024-04-27